×

Selectively altering microbiota for immune modulation

  • US 10,363,308 B2
  • Filed: 11/15/2018
  • Issued: 07/30/2019
  • Est. Priority Date: 06/05/2016
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a cancer in a patient, wherein the method comprises(a) exposing a microbiota in the patient to a guided nuclease to selectively target the genome of cells of a first species in the microbiota using the guided nuclease, wherein the first species is a bacterial or archaeal species;

  • and simultaneously or sequentially administering to the patient an effective amount of an immunotherapy; and

    (b) allowing the guided nuclease to cut one or more target nucleotide sequences comprised by first cells of a first strain of the first species, thereby killing the first cells or reducing the growth thereof, whereby the proportion of the first cells comprised by the microbiota is reduced;

    wherein(c) the selective targeting avoids targeting second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the first cells; and

    (d) the reducing of the proportion of the first cells modulates immune cells in the patient, whereby the efficacy of the immunotherapy is enhanced for treatment of the cancer in the patient.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×